Research
Metabolic adaptation
GLP-1 RAs may enhance traditional OSA treatments, offering an integrated approach targeting the root cause of obesity in OSA.
Practitioners should consider integrating GLP-1 RAs into OSA management strategies.
StrongSupportsmedium confidence
Emerging clinical trials suggest that GLP-1 RAs may enhance traditional OSA treatments, offering an integrated approach targeting the root cause of obesity in OSA.
Why this rating
The claim is based on emerging clinical trials referenced in the abstract.
Source
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review
Ali El-Solh et al. · Expert Opinion on Pharmacotherapy · 2024
DOI 10.1080/14656566.2024.2437525
reviewCited 21×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) may improve obstructive sleep apnea (OSA) symptoms by reducing fat deposition around the upper airway and decreasing systemic inflammation.Strong
- GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →